Need some help?
Our team at Aurolab is here to assist you in finding the right ophthalmic solutions tailored to your clinical needs. Reach out to us for personalized product recommendations, technical specifications, or distribution support.
Auromox
Regular price
Rs. 0.00
Couldn't load pickup availability
Share your supplement results across social platforms!
Your wellness starts here!
All our products are carefully packaged and come with clear instructions. Shop with confidence and take the next step toward a healthier, more vibrant you!
AUROMOX (Moxifloxacin 0.5%) is a sterile, preservative-free antibiotic used during ophthalmic surgery to prevent postoperative infections such as endophthalmitis. Administered directly into the anterior chamber, it provides rapid, broad-spectrum antimicrobial coverage against common ocular pathogens. A fourth-generation fluoroquinolone formulation, Aurromox offers a broad-specturm antibacterial action against Gram-positive, Gram-negative, atypical microorganisms, and anaerobes. The solution enhances surgical safety by effectively reducing the risk of infection while maintaining corneal endothelial health.
KEY FEATURES:
- Broad-spectrum fluoroquinolone antibiotic effective against common ocular pathogens.
- Delivered intracamerally for prophylaxis against postoperative endophthalmitis.
- Preservative-free and isotonic formulation minimize ocular toxicity and irritation.
- Rapid onset of action ensuring effective antimicrobial effect during and after surgery.
- Demonstrated safety with minimal anterior chamber reaction and no significant corneal toxicity.
- Supplied in 1ml vial, packed in with a pouch pack of five vials.
SCIENTIFIC STUDIES:
ESCRS STUDY:
Endophthalmitis reduction with intracameral moxifloxacin in eyes with and without surgical complications: Results from 2 million consecutive cataract surgeries.
Aravind Haripriya, MD, David F. Chang, MD, Ravilla D. Ravindran, MD
- Published in ESCRS, this landmarks a study of over 2.2 million cataract surgeries at Aravind Eye Hospitals found that Auromox (Intracameral Moxifloxacin) lowered post-operative endophthalmitis rates from 0.07% to 0.02%.
- Auromox worked for both surgery types and reduced infection risk after posterior capsular rupture from 0.43% to 0.18%, especially aiding secondary IOL implantations.
- https://www.sciencedirect.com/science/article/abs/pii/S0886335019303153
AAO STUDY:
Endophthalmitis reduction with intracameral moxifloxacin prophylaxis
Aravind Haripriya, MD, David F. Chang, MD, Ravilla D. Ravindran, MD
- A study of 3,02,815 eyes without Auromox and 3,14,638 eyes with Auromox showed a significant drop in endophthalmitis rates from 0.07% to 0.02% (P<0.001).
- For Phaco, rates fell from 0.07% to 0.01% and for M-SICS from 0.07% to 0.02%.
- PCR increased infection risk but Auromox reduced it significantly to 0.21%.
-
https://www.sciencedirect.com/science/article/abs/pii/S0161642016307904
